Dr. Barry Kappel is the Founder, President, Chief Executive Officer and Director of Sapience Therapeutics. Prior to founding Sapience, Dr. Kappel was a senior executive of ContraFect Corporation (NASDAQ: CFRX), a company which he played an integral part in founding in 2009. Prior to ContraFect, Dr. Kappel was a Senior Consultant at Easton Associates, LLC, a boutique life science consulting firm located in Manhattan.

Dr. Kappel holds BA in Chemistry from Emory University, a PhD in Biomedical Sciences from the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan-Kettering Cancer Center, and an MBA from the S.C. Johnson Graduate School of Management at Cornell University. Dr. Kappel has published 16 peer review manuscripts, has more than 45 issued and pending patents, and was chosen as a Howard Hughes Pre-Doctoral Fellow.